Statins and the Risk of Lung Cancer: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Tan, Min ^a   Song, Xiaolian ^a   Zhang, Guoliang ^a   Peng, Aimei ^a   Li, Xuan ^a   Li, Ming ^a   Liu, Yang ^a   Wang, Changhui ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG NEOPLASMS; RISK FACTORS;

EID: 84874545071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057349     Document Type: Article

References (61)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
3. Ezzati M, Henley SJ, Lopez AD, Thun MJ, (2005) Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer 116: 963-971.
4. Wen J, Fu J, Zhang W, Guo M, (2011) Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod Pathol 24: 932-943.
5. Adcock IM, Caramori G, Barnes PJ, (2011) Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 81: 265-284.
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366: 1267-1278.
7. Newman TB, Hulley SB, (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275: 55-60.
8. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, et al. (2002) Microarray and biochemical analysis of lovastatin-induced apotosis of squamous cell carcinoma. Neoplasia 4: 337-346.
9. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, et al. (1998) Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157: 1616-1622.
10. Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, et al (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 7: e29849.
11. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Available: http://www.cochrane-handbook.org/. Accessed 2012 Dec 26.
12. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2012 Dec 26.
13. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
14. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
15. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
16. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, et al. (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105: 2341-2346.
17. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002) PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630.
18. Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, Parish S, et al (2011) Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 378: 2013-2020.
19. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease) (2002) Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359: 1379-1387.
20. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, et al. (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J 32: 2525-2532.
21. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S, (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67: 99-109.
22. Yang X, So WY, Ma RC, Ko GT, Kong AP, et al. (2009) Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 32: 1826-1832.
23. Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, et al. (2011) Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 58: 530-537.
24. Sato S, Ajiki W, Kobayashi T, Awata N, (2006) PCS Study Group (2006) Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 16: 201-206.
25. Karp I, Behlouli H, Lelorier J, Pilote L, (2008) Statins and cancer risk. Am J Med 121: 302-309.
26. Haukka J, Niskanen L, Partonen T, Lönnqvist J, Tiihonen J, (2012) Statin usage and all-cause and disease-specific mortality in a nationwide study. Pharmacoepidemiol Drug Saf 21: 61-69.
27. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288: 2998-3007.
29. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, et al. (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287: 3215-3222.
30. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, et al. (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364: 771-777.
31. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, et al. (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357: 1477-1486.
32. Blais L, Desgagné A, LeLorier J, (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160: 2363-2368.
33. Kaye JA, Jick H, (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90: 635-637.
34. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ, (2004) The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394.
35. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, et al. (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114: 643-647.
36. Coogan PF, Rosenberg L, Strom BL, (2007) Statin use and the risk of 10 cancers. Epidemiology 18: 213-219.
37. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S, (2007) Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115: 27-33.
38. Khurana V, Bejjanki HR, Caldito G, Owens MW, (2007) Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131: 1282-1288.
39. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, et al. (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100: 134-139.
40. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, et al. (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17: 27-36.
41. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, et al. (2010) Incidence of cancer and statin usage--record linkage study. Int J Cancer 126: 279-284.
42. Hippisley-Cox J, Coupland C, (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340: c2197.
43. Vinogradova Y, Coupland C, Hippisley-Cox J, (2011) Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 11: 409.
44. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM, (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71: 1763-1771.
45. Cheng MH, Chiu HF, Ho SC, Yang CY, (2012) Statin use and the risk of female lung cancer: a population-based case-control study. Lung Cancer 75: 275-279.
46. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for ystematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med51: 264-269 W264.
47. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM, (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25: 3462-3468.
48. Cui X, Xie Y, Chen M, Li J, Liao X, et al. (2012) Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 23: 1099-1111.
49. Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, et al. (2010) can statin therapy reduce the risk of melanoma? a meta-analysis of randomized controlled trials. EUR J EPIDEMIOL 25: 29-35.
50. undela k, srikanth v, bansal d, (2012) statin use and risk of breast cancer: a meta-analysis of observational studies. breast cancer res treat 135: 261-269.
51. Taylor ML, Wells BJ, Smolak MJ, (2008) Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 17: 259-268.
52. Browning DR, Martin RM, (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120: 833-843.
53. Kuoppala J, Lamminpää A, Pukkala E, (2008) Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 44: 2122-2132.
54. Wong WW, Dimitroulakos J, Minden MD, Penn LZ, (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519.
55. buhaescu i, izzedine h, (2007) mevalonate pathway: a review of clinical and therapeutical implications. clin biochem 40: 575-584.
56. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, et al. (2006) potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of ras isoforms in growth factor signaling. oncogene 25: 877-887.
57. Maksimova E, Yie TA, Rom WN, (2008) in vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. lung 186: 45-54.
58. Han JY, Lim KY, Yu SY, Yun T, Kim HT, et al. (2011) A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer 117: 2178-2185.
59. Han JY, Lee SH, Yoo NJ, Hyung LS, Moon YJ, et al. (2011) A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 17: 1553-1560.
60. Nielsen SF, Nordestgaard BG, Bojesen SE, (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367:1792-1802.
61. Caporaso NE (2012) Statins and cancer-related mortality--let's work together. N Engl J Med 367:1848-1850